IMA101

IMA101 is a personalized, multi-target adoptive cell therapy (ACT) developed for the treatment of advanced or metastatic solid tumors. The therapy involves isolating a patient’s own T cells (autologous), priming and expanding them ex vivo to specifically target up to four tumor-associated peptide-HLA (pHLA) antigens identified in the patient’s tumor tissue. These targets are selected from a predefined warehouse of cancer antigens including COL6A3 exon 6, PRAME, MAGEA1, MAGEA4, MAGEA8, CTAG1A/NY-ESO-1, MXRA5, and MMP1. After lymphodepleting chemotherapy with fludarabine and cyclophosphamide and low-dose interleukin-2 support post-infusion (± atezolizumab in some cohorts), the expanded T cells are reinfused intravenously into the patient. The approach aims to overcome challenges such as tumor heterogeneity and immune escape by targeting multiple antigens simultaneously using high-affinity TCRs. Clinical studies have demonstrated feasibility and tolerability; most common adverse events include cytokine release syndrome (Grade 1–2) and cytopenias associated with pre-conditioning[3][4][5][8].

Other names

ex vivo-expanded autologous T cells IMA101ACTolog